Skip to main content

Table 5 MTHFR A1298C and breast cancer survival

From: Association of MTHFR gene polymorphisms with breast cancer survival

  Person-years1 # events2 HR (95% CI)3 p-value
A1298C genotype (n = 198)     
   A/A    1  
   A/C or C/C 873 46 2.05 (1.05–4.00) 0.03
ER-negative (n = 84)     
   A/A    1  
   A/C or C/C 352 29 2.70 (1.17–6.23) 0.02
ER-positive (n = 114)     
   A/A    1  
   A/C or C/C 521 17 1.39 (0.43–4.48) 0.58
African-American (n = 121)     
   A/A    1  
   A/C or C/C 520 29 1.57 (0.70–3.56) 0.28
Caucasian (n = 77)     
   A/A    1  
   A/C or C/C 352 17 6.28 (1.25–31.7) 0.03
No Chemotherapy (n = 81)     
   A/A    1  
   A/C or C/C 394 13 7.50 (1.49–37.7) 0.01
Chemotherapy (n = 117)     
   A/A    1  
   A/C or C/C 479 33 1.62 (0.76–3.46) 0.21
  1. 1 Time at risk in person-years. 2 Number of deaths due to breast cancer. 3 Cox Proportional-Hazards regression with adjustments for age at diagnosis, race, C677T, BMI, estrogen receptor, TNM stage, and chemotherapy.
\